A Study of LY3502970 in Healthy Overweight and Obese Participants

Lilly

Status and phase: Completed; Phase 1

Conditions: Obese; Healthy

Treatments: Drug: LY3502970

Study type: Interventional

Funder types: Industry

Identifiers

NCT05313802

18453

J2A-MC-GZGK (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.

Enrollment: 72 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participants with stable body weight for at least one month prior to randomization.
• Participants with body mass index (BMI) of greater than or equal to (≥) 27.0 kilograms per meter squared (kg/m²)
• Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential

Exclusion criteria

• Have known allergies to LY3502970 or other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs
• Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders
• Have any type of diabetes with hemoglobin A1c (HbA1c) ≥6.5 %

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

72 participants in 3 patient groups

LY3502970 (Dose Level 1)

Experimental group

Description:

LY3502970 administered orally.

Treatment:

Drug: LY3502970

LY3502970 (Dose Level 2)

Experimental group

Description:

LY3502970 administered orally.

Treatment:

Drug: LY3502970

LY3502970 (Dose Level 3)

Experimental group

Description:

LY3502970 administered orally.

Treatment:

Drug: LY3502970